Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin J Epstein

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|April 27, 2007
Drug evaluation: PSN-9301, a short-acting inhibitor of dipeptidyl peptidase IVBenjamin J Epstein
Expert Opinion on Pharmacotherapy|July 2, 2010
Improving blood pressure control rates by optimizing combination antihypertensive therapyBenjamin J Epstein
Vascular Health and Risk Management|September 23, 2010
Aliskiren and valsartan combination therapy for the management of hypertensionBenjamin J Epstein
Pharmacotherapy|May 28, 2004
Elevations in serum creatinine concentration: concerning or reassuring?Benjamin J Epstein
The New England Journal of Medicine|December 6, 2002
Drug resistance among patients recently infected with HIVBenjamin J Epstein
The Annals of Pharmacotherapy|December 16, 2004
Comment: renal protective effects of angiotensin receptor blockersBenjamin J Epstein
The Annals of Pharmacotherapy|June 5, 2008
Efficacy and safety of darusentan: a novel endothelin receptor antagonistBenjamin J Epstein
Expert Review of Cardiovascular Therapy|June 10, 2009
Endothelin receptor antagonists as antihypertensives: the next frontierBenjamin J Epstein, Shawn Anderson
Pharmacotherapy|August 29, 2007
Discordant effects of beta-blockade on central aortic systolic and brachial systolic blood pressure: considerations beyond the cuffBenjamin J Epstein, Shawn Anderson
Journal of Pharmacy Practice|April 22, 2011
Nonpharmacological interventions for the treatment of rheumatoid arthritis: a focus on mind-body medicineDonna Leverone, Benjamin J Epstein
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Current Opinion in Investigational Drugs (London, England : 2000)|April 27, 2007
Drug evaluation: PSN-9301, a short-acting inhibitor of dipeptidyl peptidase IVBenjamin J Epstein
Expert Opinion on Pharmacotherapy|July 2, 2010
Improving blood pressure control rates by optimizing combination antihypertensive therapyBenjamin J Epstein
Vascular Health and Risk Management|September 23, 2010
Aliskiren and valsartan combination therapy for the management of hypertensionBenjamin J Epstein
Pharmacotherapy|May 28, 2004
Elevations in serum creatinine concentration: concerning or reassuring?Benjamin J Epstein
The New England Journal of Medicine|December 6, 2002
Drug resistance among patients recently infected with HIVBenjamin J Epstein
The Annals of Pharmacotherapy|December 16, 2004
Comment: renal protective effects of angiotensin receptor blockersBenjamin J Epstein
The Annals of Pharmacotherapy|June 5, 2008
Efficacy and safety of darusentan: a novel endothelin receptor antagonistBenjamin J Epstein
Expert Review of Cardiovascular Therapy|June 10, 2009
Endothelin receptor antagonists as antihypertensives: the next frontierBenjamin J Epstein, Shawn Anderson
Pharmacotherapy|August 29, 2007
Discordant effects of beta-blockade on central aortic systolic and brachial systolic blood pressure: considerations beyond the cuffBenjamin J Epstein, Shawn Anderson
Journal of Pharmacy Practice|April 22, 2011
Nonpharmacological interventions for the treatment of rheumatoid arthritis: a focus on mind-body medicineDonna Leverone, Benjamin J Epstein
Pageof 3